Cancer Network

💬 Bringing up the subject of death or dying, and acknowledging mortality, may be a difficult subject among oncologists. In the latest collaborative podcast with American Psychosocial Oncology Society, Daniel McFarland, DO, from University of Rochester spoke with William Breitbart, MD, of Memorial Sloan Kettering Cancer Center, regarding this topic.   🎧 Listen to the full discussion today, and gain valuable insights on this aspect of oncology care. https://lnkd.in/ed3zPbEd

Patients with multiple myeloma who received an antiemetic regimen--palonosetron, dexamethasone, aprepitant, and olanzapine--achieved a 44.1% CR rate across all study phases. https://hubs.li/Q03N041j0 #mmsm #cancer #oncology

At #SOHO2025, we spoke with hematologic malignancy experts about new data and hot topics surrounding the current HemeOnc treatment landscape. 🎥 Watch our new YT video here: https://hubs.li/Q03N6PWy0 #HemeOnc #mmsm #lymsm #leusm

Listen to Raed M. Al-Rajabi, MD, discuss the state of immune effector cell therapy in GI malignancies. #ICE_TCongress25 | The University of Kansas Cancer Center

WTX-124 achieved clinically meaningful anti-tumor activity with a tolerable safety profile in patients with cutaneous melanoma who received prior treatment with immune checkpoint inhibitors. https://hubs.li/Q03M__qb0 #melsm #cancer #oncology

Optimizing Care for Advanced Epithelioid Sarcoma: What Every Oncology Team Should Know Epithelioid sarcoma poses unique challenges—from diagnosis to treatment to surveillance. In this Around the Practice series, Neeta Somaiah, MD, Edwin Choy, MD, PhD, and Brian Rubin, MD, PhD, explore how to refine each step of the care pathway: ✔️Enhancing diagnostic accuracy through imaging, histology, and molecular markers (e.g. INI1 loss) ✔️Structuring multidisciplinary collaboration to streamline decision-making ✔️Integrating emerging therapies and personalized strategies to extend outcomes Whether you're a surgical oncologist, pathologist, medical oncologist, or part of a multidisciplinary care team, this program offers actionable frameworks for a complex disease. ▶️ Watch now: https://hubs.li/Q03N0qYY0 #Sarcoma #EpithelioidSarcoma #PrecisionOncology #RareCancer #CancerNetwork

T-DXd plus pertuzumab achieved a median PFS per BICR of 40.7 months vs 26.9 months with standard of care in the phase 3 DESTINY-Breast09 trial. https://hubs.li/Q03MRLVF0 #bcsm #cancer #oncology

Is it time to talk about a cure in multiple myeloma? Jagannath Sundar, MBBS, thinks so. #mmsm #SOHO2025 #cancer | Icahn School of Medicine at Mount Sinai

The future of your oncology career starts here. Sign up now for CancerNetwork’s Career Center—an exclusive hub for job opportunities, leadership training, and professional growth. https://hubs.li/Q03Mx9840

Among 82 patients with prostate cancer with nodal recurrence previously treated with radiotherapy treated with salvage nodal radiation therapy, one grade 2 GU toxicity and five grade 2 GI toxicities occurred. https://hubs.li/Q03MRys20 #pcsm #cancer #ASTRO25